RESECT Overview


Transurethral REsection and Single instillation intra-vesical chemotherapy Evaluation in bladder Cancer Treatment (RESECT) Improving quality in TURBT surgery.
RESECT is a new GLOBAL prospective multi-centre international observational study starting in 2020.
Status Update – 15/10/2020 : Over 600 collaborators have now pre-registered to take part in RESECT from more than 50 countries across the globe! The RESECT protocol is being finalised. We are working hard to ensure the study can launch later this year as clinic practice returns to normal after the COVID-19 pandemic.

RESECT Overview


Background:
Superficial bladder cancer, known as non-muscle-invasive bladder cancer (NMIBC) is the most common type of bladder cancer. It is expensive to manage. This is because there is a high burden of recurrent disease after initial treatment and need for long term surveillance for recurrence.
The most important step in the diagnosis and treatment of NMIBC is the first surgical procedure called the transurethral resection of bladder tumour (TURBT). This procedure is crucial in properly grading and staging the disease (thus determining the next appropriate treatment) and in potentially providing a curative treatment for certain cases. There is evidence that the quality of the TURBT operation, and the use of a single instillation postoperative intravesical chemotherapy (SI-IVC) with Mitomycin-C, can reduce cancer recurrence rates and progression to more invasive cancer. Despite this, there is anecdotal evidence that the quality of TURBT surgery and the usage of intravesical chemotherapy varies widely between hospitals and thus may result in worse outcomes for some.


Aims:
To conduct a retrospective and prospective, multicentre, international study of urological practice of the management of NMIBC. Our aim is to measure the achievement of TURBT quality indicators across hospitals, regions and countries and compare these against evidence-based recommendations. We aim to determine if any hospital, service, training or technical factors impact the achievement of quality indicators and/or early recurrence rates. We aim to use these data to present hospital and clinician performance back to surgeons, as a method of driving quality improvement.


RESECT aims to answer some key UNKNOWNS:
  1. What things should we measure to determine TURBT quality?
  2. What rate of achievement should we aim for in our practice?
  3. What factors are associated with better achievement of TURBT quality?
  4. Does reporting and comparing our TURBT quality make us do it better?

RESECT Infographic


RESECT Team


Lead trainees – Mr Kevin Gallagher and Miss Nikita Bhatt

Chief Investigator – Mr Veeru Kasivisvanathan (BURST Chair, Academic Clinical Lecturer in Uro-Oncology, University College London, London)

Core team members – Mr Keiran Clement, Miss Eleanor Zimmermann, Mr Taimur Shah, Mr Sinan Khadhouri, Miss Meghana Kulkarni, Dr Chuanyu Gao, Dr Chon Meng Lam, Dr Alexander Light, Miss Keerthanaa Jayaraajan, Miss Aqua Asif, Dr Thineskrishna Anbarasan, Mr Vinson Chan

Steering group members – Dr Steven MacLennan (Research Fellow, University of Aberdeen), Mr Param Mariappan (Consultant Urologist, Western General Hospital, Edinburgh), Mr Tim O’Brien (Consultant Urologist, Guy’s and St Thomas’, London), Professor Matthew Nielsen, University of North Carolina, USA.

Patient and Public involvement – Jacqueline Emkes, Rachel Jury

Overview of RESECT registrations


Click to view interactive map

RESECT Sponsors


Copyright British Urology Researchers in Surgical Training (BURST) Research Collaborative @ 2020.